Viridian Therapeutics (VRDN) investor relations material

Business and pipeline overview

• Two months into Lumvoa IV launch with strong operational execution and broad physician engagement.

• Preparing BLA submission for subcutaneous elegrobart in thyroid eye disease, targeting Q1 2027.

• TSHR antagonist IND submission planned for Q4 this year, with clinical entry early next year.

• FcRn program progressing through first-in-human trials, with data and development plans to be disclosed this year.

• Fc fragment program met IgG suppression thresholds and is albumin sparing; future direction depends on half-life extended FcRn data.

Lumvoa IV launch and market strategy

• Achieved 95% engagement with 2,000 core prescribers within six weeks of launch.

• Payer research and pre-approval exchanges support parity pricing and coverage, leveraging TEPEZZA’s established footprint.

• Early demand indicators show broad and deep physician and patient interest, with multiple scripts per prescriber.

• Commercial messaging emphasizes rapid onset, robust chronic data, and reduced treatment burden (five infusions vs. eight for TEPEZZA).

• Chronic data included in label, with strong proptosis and diplopia resolution rates, differentiating from competitors.

Patient access, reimbursement, and operational logistics

• ViridianCares program supports patients, physicians, and infusion centers through benefit verification and prior authorization.

• Prior authorization for Lumvoa may take up to 90 days, similar to TEPEZZA, with revenue recognition lagging early demand.

• Enrollment forms are streamlined to minimize friction and reflect drug profile advantages.

• Extended payment terms and early J-code application reduce reimbursement risk for infusion centers; permanent J-code expected January 1.